|
Hemodynamic and gas exchange response to inhaled nitric oxide (INO), dobutamine, and INO plus dobutamine in cystic fibrosis (8 patients) |
||||
| Baseline |
INO |
Dobutamine |
INO+Dobutamine |
|
|
|
||||
| Cardiac index (l/min/m2) |
3.6 ± 0.6 |
3.6 ± 0.5 |
5.1± 0.6 |
4.7± 0.5** |
| Heart rate (beats/min) |
90 ± 26 |
90 ± 25 |
102 ± 22 |
104 ± 18 |
| SVI (ml/m2) |
43 ± 12 |
43 ± 10 |
52 ± 10 |
47 ± 7 |
| CVP (mmHg) |
1.4 ± 1.9 |
1.6 ± 2.1 |
1.9 ± 2.4 |
1.4 ± 2 |
| MPAP (mmHg) |
24 ± 4 |
22 ± 3 |
26 ± 5 |
24 ± 3 |
| PAOP (mmHg) |
5.7 ± 2.7 |
6.5 ± 3.5 |
6.2 ± 3.3 |
5.6 ± 2.6 |
| MPAP-PAOP (mmHg) |
18 ± 2 |
16 ± 2* |
20 ± 2 |
18 ± 3 |
| PVRI (dyne/s/cm5/m2) |
591 ± 148 |
548 ± 140 |
448 ± 96* |
460 ± 98* |
| MAP (mmHg) |
83 ± 15 |
83 ± 11 |
87 ± 13 |
89 ± 13 |
| SVRI (dyne/s/cm5/m2) |
1826 ± 261 |
1825 ± 230 |
1371 ± 193 |
1495 ± 197** |
| Qs/Qt (%) |
20 ± 7 |
17 ± 4 |
30 ± 6* |
22 ± 5 |
| PaO2/FiO2 (mmHg) |
276 ± 56 |
350 ± 48* |
260 ± 56 |
319 ± 65 |
| PaCO2 (mmHg) |
54 ± 11 |
55 ± 11 |
54 ± 12 |
53 ± 12 |
|
*P < 0.05; **P < 0.01. CVP, cardiovenous pressure; INO, inhaled nitric oxide; MAP, mean systemic arterial pressure; MPAP, mean pulmonary arterial pressure; PAOP, pulmonary artery occluded pressure; PVRI, pulmonary vascular resistance index; SVI, systemic vascular index; SVRI, systemic vascular resistance index. | ||||
Vizza et al. Critical Care 2001 5:355 doi:10.1186/cc1069 |
||||